Inovio has struck a manufacturing deal for its coronavirus vaccine with Thermo Fisher Scientific.
Inovio is reportedly planning to produce 100 million doses of its vaccine candidate by next year using contract manufacturers. In addition to Thermo, Inovio has also struck manufacturing deals with Richter-Helm BioLogics and Ology Biosciences.
The company is currently getting ready to launch phase 3 trials of its vaccine, pending FDA approval.
Three other candidates — from AstraZeneca, Moderna and Pfizer/BioNTech — are already in late-stage trials.
Read the Reuters report.
